Preventive cardiology for the aging population: how can we better design clinical trials of statins?

Area of Science:

• Gerontology
• Cardiovascular Medicine
• Neuroscience

Background:

• The global population of older adults is rapidly increasing.
• While lifespan has increased, quality of life in older age, including cognitive function and physical health, has not proportionally improved.
• Common health issues in older adults include frailty, memory decline, cardiovascular disease (CVD), and neurodegenerative diseases.

Purpose of the Study:

• To evaluate the efficacy of statin therapy in older populations (aged over 70).
• To determine the effects of statins on mortality, disability, and neurocognitive outcomes in the elderly.
• To clarify the role of statins in primary prevention for individuals aged 70 and above, and inform treatment strategies for those over 80.

Main Methods:

• Ongoing large-scale clinical trials are the primary method of investigation.
• These trials utilize endpoints including mortality, disability, neurocognitive function, and standard cardiovascular disease outcomes.
• Subgroup analyses from existing meta-analyses of statin trials in middle-aged populations provide preliminary evidence.

Main Results:

• Statins are established to reduce CVD events in middle-aged individuals.
• Evidence suggests similar benefits in older populations for primary prevention, though clarity diminishes with advanced age.
• The precise impact of statins on mortality, disability, and dementia in the elderly, considering drug metabolism, efficacy, and comorbidities, requires further determination.

Conclusions:

• Two major trials are currently underway to definitively assess statin efficacy in individuals over 70.
• These studies aim to provide crucial data on statins' effects on cardiovascular health, cognitive function, and overall longevity in older adults.
• Findings from these trials will guide clinical practice regarding statin use in the elderly, particularly those over 80.